


10/576527  
IAP15 Rec'd PCT/PTO 19 APR 2006

PATENT  
Customer No. 22,852  
Attorney Docket No. 08201.0042-00000

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re National Stage of International )  
Application No. PCT/US2004/034514 of: )  
KALLED, Susan et al. )  
Application No.: To be assigned ) Group Art Unit: To be assigned  
PCT Application Filed: 20 October 2004 )  
§ 371 date: 20 October 2003 ) Examiner: To be assigned  
For: THERAPEUTIC REGIMENS FOR ))  
BAFF ANTAGONISTS ) CERTIFICATE UNDER 37 CFR § 1.10 OF  
 ) MAILING BY "EXPRESS MAIL"  
)

I hereby certify that this correspondence is being deposited with  
the United States Postal Services "Express Mail Post Office to  
Addressee" service under 37 CFR § 1.10 on April 19, 2006 and  
is addressed to: Commissioner for Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450. Express Mail Label No. EV  
684955995 US.

  
\_\_\_\_\_  
Kathleen Camire

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of  
the Examiner the documents on the attached listing. This Information Disclosure  
Statement is being filed within three months of the date of entry of the national stage  
in an international application.

Copies of the listed foreign and non-patent literature documents are attached.

Copies of the U.S. patent publications are not enclosed.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: 19 April 2006

By:

  
Konstantin Linnik  
Reg. No. 56,309  
Tel: (617) 452-1626

IDS Form PTO/SB/08: Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	1	of	1	Application Number	To be assigned
				Filing Date	Herewith (19 April 2006)
				First Named Inventor	Susan Kalled
				Art Unit	To be assigned
				Examiner Name	To be assigned
				Attorney Docket Number	08201.0042-00000

<b>U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS</b>					
Examiner Initials	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-			

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)			
		WO 02/024909 A2	03/28/2002	Biogen Inc.	

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			Translation <sup>6</sup>
		International Search Report for PCT/US2004/034514, mailed 6 April 2005 from the International Searching Authority of the European Patent Office.			
		Gross et al., "TACI and BCMA Are Receptors for a TNF Homologue Implicated in B-Cell Autoimmune Disease," <i>Nature</i> , 404:995-999 (2000)			
		Kayagaki et al., "BAFF/BLyS Receptor 3 Binds the B Cell Survival Factor BAFF Ligand through a Discrete Surface Loop and Promotes Processing of NF- $\kappa$ B2," <i>Immunity</i> , 10:515-524 (2002)			
		Pelletier et al., "Comparison of Soluble Decoy IgG Fusion Proteins of BAFF-R and BCMA as Antagonists for BAFF," <i>J. Bio. Chem.</i> , 278:33127-33133 (2003)			
		Stohl, W., "A Therapeutic Role For BLYS Antagonists," <i>Lupus</i> , 13:317-332 (2004)			

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.